UCB and Otsuka Pharmaceuticals Co. have signed collaboration agreements under which the two companies will co-promote the anti-epileptic drug, Keppra and Cimzia for the treatment of Crohn’s Disease, in Japan. They will also co-develop and co-promote these drugs in other indications. UCB will join Otsuka in co-promoting the anti-platelet agent Pletaal to selected accounts for a limited period. UCB will receive as much as $178 million in upfront and milestone payments as well as funding for ...